ArticleMolecular pharmaceutics2018
Near Infrared Photoimmunotherapy with Combined Exposure of External and Interstitial Light Sources.
Article in Molecular pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Combined Radiations: Biological Effects of Mixed Exposures Across the Radiation Spectrum.Biomolecules · 2025Pooled it
- Systematic review: Mechanisms of photoactive nanocarriers for imaging and therapy including controlled drug delivery.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Synergistic nanotheranostic platform for fluorescence/magnetic resonance bimodal imaging-guided near infrared photoimmuno-chemodynamic thermal targeting therapy.Journal of nanobiotechnology · 2026Article
- Adding Intratumoral Antibody-Photoabsorber Conjugate Improves Efficacy of Near-Infrared Photoimmunotherapy (NIR-PIT).Cancer science · 2026Article
- Recent advances in near-infrared dye conjugates for near-infrared photoimmunotherapy (NIR-PIT): enhancing therapeutic efficacy and immune mechanisms.RSC chemical biology · 2026Review
- Near infrared photo-bacterialflora modulation technology realized controlling periodontitis: modulation of disease-associated dysbiosis in oral microbiota using near infrared photo-antibacterial targeting therapy (NIR-PATJournal of translational medicine · 2026Article
- Carbonic anhydrase-9-targeted near-infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma.International journal of cancer · 2025Article
- Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells-A Systematic Review.Cancer management and research · 2025Review
- Contrast-enhanced ultrasound imaging for monitoring the efficacy of near-infrared photoimmunotherapy.EBioMedicine · 2023Article
- Article
- Recent advances in sonodynamic immunotherapy.Journal of cancer research and clinical oncology · 2023Review
- Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System.Pharmaceutics · 2023Review
- Pathological complete remission of relapsed tumor by photo-activating antibody-mimetic drug conjugate treatment.Cancer science · 2022Article
- Inside-the-body light delivery system using endovascular therapy-based light illumination technology.EBioMedicine · 2022Article
- Phototheranostics for multifunctional treatment of cancer with fluorescence imaging.Advanced drug delivery reviews · 2022Review
- Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect.Bioengineering & translational medicine · 2022Article
- Review
- Recent Advances in Engineering Nanomedicines for Second Near-Infrared Photothermal-Combinational Immunotherapy.Nanomaterials (Basel, Switzerland) · 2022Review
- Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.Biomedicines · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Near infrared photoimmunotherapy (NIR-PIT) is a new target-cell-specific cancer treatment that induces highly selective necrotic/immunogenic cell death after systemic administration of a photoabsorber antibody conjugate and subsequent NIR light exposure. However, the depth of NIR light penetration in tissue (approximately 2 cm) with external light sources limits the therapeutic effects of NIR-PIT. Interstitial light exposure using cylindrical diffusing optical fibers can overcome this limitation. The purpose in this study was to compare three NIR light delivery methods for treating tumors with NIR-PIT using a NIR laser system at an identical light energy; external exposure alone, interstitial exposure alone, and the combination. Panitumumab conjugated with the photoabsorber IRDye-700DX (pan-IR700) was intravenously administered to mice with A431-luc xenografts which are epithelial growth factor receptor (EGFR) positive. One and 2 days later, NIR light was administered to the tumors using one of three methods. Interstitial exposure alone and in combination with external sources showed the greatest decrease in bioluminescence signal intensity. Additionally, the combination of external and interstitial NIR light exposure showed significantly greater tumor size reduction and prolonged survival after NIR-PIT compared to external exposure alone. This result suggested that the combination of external and interstitial NIR light exposure was more effective than externally applied light alone. Although external exposure is the least invasive means of delivering light, the combination of external and interstitial exposures produces superior therapeutic efficacy in tumors greater than 2 cm in depth from the tissue surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.